Partnership Opportunity

Unlabeled Antibodies
PROGRAMPROGRAMINDICATIONSTAGE
EpratuzumabCD22Cancer/AutoimmunePhase II
VeltuzumabCD20Cancer/AutoimmunePhase II
MilatuzumabCD74Cancer/AutoimmunePhase I
IMMU-114HLA-DRCancer/AutoimmunePhase I
hR1IGF-1RCancerPreclinical
humanized BWA-3Anti-HistoneSeptic shock, ischemic stroke, glomerulonephritisPreclinical
Antibody Drug Conjugates
PROGRAMTARGETINDICATIONSTAGE
IMMU-132TROP2Solid TumorsPhase III
IMMU-130CEACAM5Solid TumorsPhase II
IMMU-140HLA-DRHematologyPreclinical
T-cell bispecificTROP2 x CD3Solid TumorsPreclinical

Technology Platform

ADC Linker

Proof-of-concept research collaboration utilizing partner’s antibodies. We have developed a proprietary antibody-drug-conjugate (ADC) linker called CL2A, designed for targeting delivery of SN-38. Click here to learn more.

DOCK-AND-LOCK®

Proof-of-concept research collaborations utilizing partner’s target and/or antibodies. DOCK-AND-LOCK ®, or DNL®, is a proprietary platform technology for creating a wide variety of multivalent antibodies of increasing complexity. Click here to learn more.

F-18 labeling

Non-exclusive licenses are available. We have invented a novel and facile method of labeling peptides with fluorine-18 (F-18) for use in imaging of diseases using position-emission tomography.